XML 18 R4.htm IDEA: XBRL DOCUMENT v3.21.2
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
CONSOLIDATED STATEMENTS OF OPERATIONS        
Net revenues $ 112,198 $ 83,431 $ 316,881 $ 253,925
Cost of revenues 61,015 46,923 173,376 147,417
Gross profit 51,183 36,508 143,505 106,508
Operating (income) expenses:        
Selling, distribution, and marketing 4,745 3,673 13,411 10,993
General and administrative 10,910 11,674 40,813 38,344
Research and development 10,759 17,644 43,646 49,096
Total operating expenses 26,414 32,991 97,870 98,433
Income (loss) from operations 24,769 3,517 45,635 8,075
Non-operating (expenses) income:        
Interest income 141 161 444 512
Interest expense (527) (175) (717) (286)
Other income (expenses), net 13,263 3,575 11,615 3,078
Total non-operating (expenses) income, net 12,877 3,561 11,342 3,304
Income (loss) before income taxes 37,646 7,078 56,977 11,379
Income tax provision (benefit) 6,686 2,285 13,436 4,490
Net income (loss) 30,960 4,793 43,541 6,889
Net income (loss) attributable to non-controlling interests 1,412 874 1,185 (787)
Net income (loss) attributable to Amphastar Pharmaceuticals, Inc. $ 29,548 $ 3,919 $ 42,356 $ 7,676
Net income (loss) per share attributable to Amphastar Pharmaceuticals, Inc. stockholders:        
Basic (in Dollars per share) $ 0.62 $ 0.08 $ 0.89 $ 0.16
Diluted (in Dollars per share) $ 0.59 $ 0.08 $ 0.85 $ 0.16
Weighted-average shares used to compute net income (loss) per share attributable to Amphastar Pharmaceuticals, Inc. stockholders:        
Basic (in Shares) 48,022 47,496 47,758 46,886
Diluted (in Shares) 50,009 49,848 49,693 48,922